Cáncer de mama metastásico: Caracterización de una cohorte según subtipos

Background: The prognosis of breast cancer (BC) is in part determined by the stage at diagnosis and its pathological characteristics. Aim: To evaluate the association between survival of women with metastatic breast cancer and pathological features of the tumor. Patients and Methods: We obtained cli...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sánchez R,César, Acevedo C,Francisco, Petric G,Militza, Galindo A,Héctor, Domínguez C,Francisco, León R,Augusto, Razmilic V,Dravna, Ceballos,Carolina, Espinoza,Fernando, Navarro O,M. Elena, Oddó B,David, Camus A,Mauricio
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2014
Materias:	Breast Neoplasms Classification Neoplasm metastasis Prognosis
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000400003
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872014000400003
record_format	dspace
spelling	oai:scielo:S0034-988720140004000032014-09-02Cáncer de mama metastásico: Caracterización de una cohorte según subtiposSánchez R,CésarAcevedo C,FranciscoPetric G,MilitzaGalindo A,HéctorDomínguez C,FranciscoLeón R,AugustoRazmilic V,DravnaCeballos,CarolinaEspinoza,FernandoNavarro O,M. ElenaOddó B,DavidCamus A,Mauricio Breast Neoplasms Classification Neoplasm metastasis Prognosis Background: The prognosis of breast cancer (BC) is in part determined by the stage at diagnosis and its pathological characteristics. Aim: To evaluate the association between survival of women with metastatic breast cancer and pathological features of the tumor. Patients and Methods: We obtained clinical and pathological data from patients diagnosed with a metastatic BC between 1999 and 2013. The expression of estrogen (ER) and progesterone (PR) receptors and human epidermal growth factor receptor 2 (HER2) was determined by immunohistochemistry. Clinicopathological subtypes were defined as: Luminal A: ER or PR positive, HER2 negative, histological grade (HG) 1 or 2; Luminal B: ER or PR positive, HER2 negative or positive or HG 3; triple negative (TN): ER, PR and HER2 negative, independent of the HG, positive HER2: ER, PR negative and HER2 positive, independent of HG. We analyzed survival based on these subtypes. Results: We identified 54 patients aged 24 to 85 years, with metastatic BC at diagnosis. Seventy five percent had luminal tumors; 19.6% HER2 positive and 7.8% were TN. In 61% of evaluable tumors, HG was classified as 3. The frequency of HER2 positive and high HG tumors was greater in these patients with metastatic BC than in a non-metastatic local BC cohort. Survival was higher among patients with Luminal tumors than in women with non-Luminal cancer (56.4 and 11.4 months, respectively, p = 0.04). Conclusions: Patients with metastatic BC at diagnosis often had HER2 positive tumors and high HG. As in other studies, ER positive tumors had a better survival.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.142 n.4 20142014-04-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000400003es10.4067/S0034-98872014000400003
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Breast Neoplasms Classification Neoplasm metastasis Prognosis
spellingShingle	Breast Neoplasms Classification Neoplasm metastasis Prognosis Sánchez R,César Acevedo C,Francisco Petric G,Militza Galindo A,Héctor Domínguez C,Francisco León R,Augusto Razmilic V,Dravna Ceballos,Carolina Espinoza,Fernando Navarro O,M. Elena Oddó B,David Camus A,Mauricio Cáncer de mama metastásico: Caracterización de una cohorte según subtipos
description	Background: The prognosis of breast cancer (BC) is in part determined by the stage at diagnosis and its pathological characteristics. Aim: To evaluate the association between survival of women with metastatic breast cancer and pathological features of the tumor. Patients and Methods: We obtained clinical and pathological data from patients diagnosed with a metastatic BC between 1999 and 2013. The expression of estrogen (ER) and progesterone (PR) receptors and human epidermal growth factor receptor 2 (HER2) was determined by immunohistochemistry. Clinicopathological subtypes were defined as: Luminal A: ER or PR positive, HER2 negative, histological grade (HG) 1 or 2; Luminal B: ER or PR positive, HER2 negative or positive or HG 3; triple negative (TN): ER, PR and HER2 negative, independent of the HG, positive HER2: ER, PR negative and HER2 positive, independent of HG. We analyzed survival based on these subtypes. Results: We identified 54 patients aged 24 to 85 years, with metastatic BC at diagnosis. Seventy five percent had luminal tumors; 19.6% HER2 positive and 7.8% were TN. In 61% of evaluable tumors, HG was classified as 3. The frequency of HER2 positive and high HG tumors was greater in these patients with metastatic BC than in a non-metastatic local BC cohort. Survival was higher among patients with Luminal tumors than in women with non-Luminal cancer (56.4 and 11.4 months, respectively, p = 0.04). Conclusions: Patients with metastatic BC at diagnosis often had HER2 positive tumors and high HG. As in other studies, ER positive tumors had a better survival.
author	Sánchez R,César Acevedo C,Francisco Petric G,Militza Galindo A,Héctor Domínguez C,Francisco León R,Augusto Razmilic V,Dravna Ceballos,Carolina Espinoza,Fernando Navarro O,M. Elena Oddó B,David Camus A,Mauricio
author_facet	Sánchez R,César Acevedo C,Francisco Petric G,Militza Galindo A,Héctor Domínguez C,Francisco León R,Augusto Razmilic V,Dravna Ceballos,Carolina Espinoza,Fernando Navarro O,M. Elena Oddó B,David Camus A,Mauricio
author_sort	Sánchez R,César
title	Cáncer de mama metastásico: Caracterización de una cohorte según subtipos
title_short	Cáncer de mama metastásico: Caracterización de una cohorte según subtipos
title_full	Cáncer de mama metastásico: Caracterización de una cohorte según subtipos
title_fullStr	Cáncer de mama metastásico: Caracterización de una cohorte según subtipos
title_full_unstemmed	Cáncer de mama metastásico: Caracterización de una cohorte según subtipos
title_sort	cáncer de mama metastásico: caracterización de una cohorte según subtipos
publisher	Sociedad Médica de Santiago
publishDate	2014
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000400003
work_keys_str_mv	AT sanchezrcesar cancerdemamametastasicocaracterizaciondeunacohortesegunsubtipos AT acevedocfrancisco cancerdemamametastasicocaracterizaciondeunacohortesegunsubtipos AT petricgmilitza cancerdemamametastasicocaracterizaciondeunacohortesegunsubtipos AT galindoahector cancerdemamametastasicocaracterizaciondeunacohortesegunsubtipos AT dominguezcfrancisco cancerdemamametastasicocaracterizaciondeunacohortesegunsubtipos AT leonraugusto cancerdemamametastasicocaracterizaciondeunacohortesegunsubtipos AT razmilicvdravna cancerdemamametastasicocaracterizaciondeunacohortesegunsubtipos AT ceballoscarolina cancerdemamametastasicocaracterizaciondeunacohortesegunsubtipos AT espinozafernando cancerdemamametastasicocaracterizaciondeunacohortesegunsubtipos AT navarroomelena cancerdemamametastasicocaracterizaciondeunacohortesegunsubtipos AT oddobdavid cancerdemamametastasicocaracterizaciondeunacohortesegunsubtipos AT camusamauricio cancerdemamametastasicocaracterizaciondeunacohortesegunsubtipos
_version_	1718436747478564864

Cáncer de mama metastásico: Caracterización de una cohorte según subtipos

Ejemplares similares